Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of NASDAQ:TRVN opened at $1.13 on Friday. The stock’s 50-day simple moving average is $1.49 and its two-hundred day simple moving average is $1.78. The stock has a market capitalization of $976,320.00, a price-to-earnings ratio of -0.02 and a beta of 1.10. Trevena has a 52-week low of $0.95 and a 52-week high of $11.25.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.